ConductScience.org, home

Paper39779554

Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches.

Sharma N and 3 others. Curr Comput Aided Drug Des, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches. Papers, record 39779554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39779554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting PD-1 in Squamous Cell Carcinoma: Flavonoid-based Therapeutics Unveiled through in silico and in vitro Approaches.
PubMed
Journal
Curr Comput Aided Drug Des
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-07-17
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
FlavonoidsMajor topic
Programmed Cell Death 1 ReceptorMajor topic
Carcinoma, Squamous CellMajor topic
Antineoplastic AgentsMajor topic
Humans
Molecular Docking Simulation
Cell Line, Tumor
Molecular Dynamics Simulation
Computer Simulation

Source PubMed

Download CSV of topics

References86

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127373242Immune checkpoint inhibitors: a milestone in the treatment of melanoma.J Dtsch Dermatol Ges2016https://conductscience.org/library/papers/27373242PubMed
235646967Investigating Cutaneous Squamous Cell Carcinoma in vitro and in vivo: Novel 3D Tools and Animal Models.Front Med (Lausanne)2022https://conductscience.org/library/papers/35646967PubMed
330243819[Beyond actinic keratoses: Field cancerization of the skin].Ann Dermatol Venereol2018https://conductscience.org/library/papers/30243819PubMed
430238167Dermatoscopy of Neoplastic Skin Lesions: Recent Advances, Updates, and Revisions.Curr Treat Options Oncol2018https://conductscience.org/library/papers/30238167PubMed
530206456Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck.Postepy Dermatol Alergol2018https://conductscience.org/library/papers/30206456PubMed
632852235Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma.Expert Rev Anticancer Ther2020https://conductscience.org/library/papers/32852235PubMed
721810686Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin.J Clin Oncol2011https://conductscience.org/library/papers/21810686PubMed
811786562Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.J Clin Oncol2002https://conductscience.org/library/papers/11786562PubMed
928964539Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.J Am Acad Dermatol2017https://conductscience.org/library/papers/28964539PubMed
1032004792Systemic treatment of patients with advanced cutaneous squamous cell carcinoma: response rates and outcomes of the regimes used.Eur J Cancer2020https://conductscience.org/library/papers/32004792PubMed
1124879468Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature.Am J Clin Oncol2016https://conductscience.org/library/papers/24879468PubMed
1228252823Node-positive cutaneous squamous cell carcinoma of the head and neck: Survival, high-risk features, and adjuvant chemoradiotherapy outcomes.Head Neck2017https://conductscience.org/library/papers/28252823PubMed
1333572373Cutaneous Squamous Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines2021https://conductscience.org/library/papers/33572373PubMed
1423945592Signatures of mutational processes in human cancer.Nature2013https://conductscience.org/library/papers/23945592PubMed
1525765070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
1626788324Novel technologies and emerging biomarkers for personalized cancer immunotherapy.J Immunother Cancer2016https://conductscience.org/library/papers/26788324PubMed
1730837075Immunotherapy in Nonmelanoma Skin Cancer.Actas Dermosifiliogr (Engl Ed)2019https://conductscience.org/library/papers/30837075PubMed
1828716069Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.J Immunother Cancer2017https://conductscience.org/library/papers/28716069PubMed
1927151159Cancer immunotherapy: the beginning of the end of cancer?BMC Med2016https://conductscience.org/library/papers/27151159PubMed
2031196207Combination of CTLA-4 and PD-1 blockers for treatment of cancer.J Exp Clin Cancer Res2019https://conductscience.org/library/papers/31196207PubMed

See all 86 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
40386063Screening and identification of versican as a sensitive biomarker and potential therapeutic target in basal cell carcinoma.Int J Med Sci2025https://conductscience.org/library/papers/40386063

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39779554

GET https://conductscience.org/api/papers/v1/39779554/references?page=2